J Neurol Neurosurg Psychiatry 81:1336-1340 doi:10.1136/jnnp.2009.191239
  • Research paper

A 15-year prospective longitudinal study of disease progression in patients with HTLV-1 associated myelopathy in the UK

  1. Graham P Taylor1,2
  1. 1National Centre for Human Retrovirology, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK
  2. 2Section of Infectious Diseases, Faculty of Medicine, Imperial College, London, UK
  1. Correspondence to Dr Fabiola Martin, National Centre for Human Retrovirology, Imperial College Healthcare NHS Trust, St Mary's Hospital, London W2 1NY, UK; f.martin{at}
  1. Contributors All authors contributed to data collection. FM collated and analysed the data and wrote the article. GPT designed the study and coauthored the article.

  • Received 12 August 2009
  • Revised 14 February 2010
  • Accepted 16 February 2010
  • Published Online First 26 July 2010


Background The natural history of HTLV-1-associated myelopathy (HAM) has been mainly described in HTLV-1 endemic countries such as Japan, Brazil and Martinique.

Objectives The authors describe the natural history of the largest cohort of patients with HAM living in the UK from 1993 to 2007.

Methods Prospective, longitudinal study comparing clinical and virological outcome between first and last clinical visit. Incidence and cause of death were documented and the mortality calculated.

Results 48 patients were included: 79.2% were female, 79.2% were of Afro-Caribbean origin, and 83.3% acquired HTLV-1 through breastfeeding or unprotected heterosexual intercourse. The mean age of onset was 46 years. The median durations from onset of symptoms to diagnosis and to last follow-up were 2 and 11.6 years. The median time of follow-up was 3.8 years. The most common first recalled symptom was unilateral leg weakness. The median times from onset to unilateral, bilateral walking aid and frame or a wheelchair were 11, 11.2, 11.3 and 18 years. The overall average deterioration in timed walk in patients whose need for aid did not change was 2 s/10 m/year. Three patients progressed rapidly and were unable to walk within 2 years. Six patients were slow/non-progressors. The mortality was 2.4/100 person year follow-up. The median HTLV-1 viral load remained unchanged at 14%.

Conclusions HAM is a slowly progressing chronic disease. Timed walk deteriorates by 2 s/10 m/year, and patients remain ambulant for 10 years but become wheelchair-dependent a decade later. HTLV-1 viral load remains high and unchanged over time regardless of clinical progression.


  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Visit the full archive of podcasts for JNNP here >>

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article